Nexalin Technology

Nexalin Technology Capital Expenditures

The Capital Expenditures (CapEx) of Nexalin Technology (NXL) as of Oct 18, 2026 is -96,859.00 USD. In the previous year, Capital Expenditures (CapEx) was -170,306.00 USD — a change of -43.13% (higher).

Capital Expenditures

-96,859.00USD

YoY

-43.13%

Last updated:

Capital Expenditures (CapEx) of Nexalin Technology is 2025 -96,859.00 USD. Capital Expenditures (CapEx) of Nexalin Technology was 2024 -170,306.00 USD. It decreases by -43.13% higher compared to the previous year.

The Nexalin Technology Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2019
-4.00 USD
Jan 1, 2020
-648.00 USD
Jan 1, 2021
-1.00 USD
Jan 1, 2022
-1.00 USD
Jan 1, 2023
-109,279.00 USD
Jan 1, 2024
-170,306.00 USD
Jan 1, 2025
-96,859.00 USD
The Nexalin Technology Capital Expenditures history
YEARCapital ExpendituresYoY
-96,859.00USD-43.13%
-170,306.00USD+55.85%
-109,279.00USD+10.93 M%
-1.00USD0.00%
-1.00USD-99.85%
-648.00USD+16,100.00%
-4.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nexalin Technology Stock analysis

What does Nexalin Technology do? Nexalin Technology Inc, headquartered in Laguna Niguel, California, designs and develops neurostimulation products within the US health care sector. Listed on September 16, 2022, the company employs six full-time staff members. Its flagship device, Generation 1, utilizes bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The non-invasive system applies a high-frequency, charge-balanced electrical current waveform via head electrodes, offering relief without adverse side effects. Additionally, Nexalin is designing clinical trials for Generation 2, targeting substance use disorders, particularly opiate abuse, as well as chronic pain, Alzheimer’s disease, and dementia. These devices operate using varying voltages and frequencies to address mental health issues effectively. Nexalin Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nexalin Technology stock

Capital Expenditures (CapEx) of Nexalin Technology is -96,859.00 USD in 2025.

Capital Expenditures (CapEx) of Nexalin Technology changed from -170,306.00 USD to -96,859.00 USD, representing a -43.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Nexalin Technology since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Nexalin Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Nexalin Technology

All Key Metrics — Nexalin Technology